Inhibit crucial proteins in OSCC by molecular docking; reducing p38 phosphorylation and downregulating matrix metalloproteinase (MMP)-2 expression; promising candidates for the development of targeted anti-cancer therapies against OSCC [238]. The gene discussed is MMP2; the disease is cancer.